ActHIB

Phase 3Biologic

GSK

ActHIB is one of 39 biologic programs targeting Influenza. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

InfluenzaActive, not recruiting

DiphtheriaActive, not recruiting

InfluenzaPhase 2

Active, not recruiting

DiphtheriaPhase 3

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Fluzone

Sanofi

Preclinical

16 2

ActHIB

GSK

Phase 3

1 3

Trexall

Alnylam Pharmaceuticals

Preclinical

1 4

Crestor

AstraZeneca

Preclinical

1 5

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 6

COMIRNATY

Pfizer

Preclinical

1 7

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

1 8

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

14 9

PD-1/PD-L1 Inhibitors

CChuangzhen Chen

Preclinical

1 10

Fluvirin

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immunogenicity5 trials

A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers

Unknown status·NNuron Biotech Inc.·Phase 2·NCT01732198·220 enrolled

Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants

Completed· GSK logo

GSK·Phase 3·NCT01000974·4,003 enrolled

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

Completed· GSK logo

GSK·Phase 3·NCT00289783·4,441 enrolled

Show 2 more trials

Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01337167·1,473 enrolled

Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

Completed· GSK logo

GSK·Phase 3·NCT02096263·585 enrolled

Vaccine3 trials

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age

Completed· GSK logo

GSK·Phase 3·NCT00345579·4,432 enrolled

Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine

Completed· GSK logo

GSK·Phase 2·NCT00129129·756 enrolled

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

Completed· GSK logo

GSK·Phase 3·NCT00614614·1,558 enrolled

Diphtheria1 trial

Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months

Completed· GSK logo

GSK·Phase 3·NCT00197236·468 enrolled

Vaccines1 trial

Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines

Completed· GSK logo

GSK·Phase 2·NCT00134719·1,104 enrolled

Influenza1 trial

Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine

Completed· GSK logo

GSK·Phase 2·NCT00127855·409 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for ActHIB. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ActHIB compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ActHIB. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: GSK

ActHIB

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Immunogenicity5 trials

Vaccine3 trials

Diphtheria1 trial

Vaccines1 trial

Influenza1 trial

References

Drug Info

Quick Facts

Related News